National Institute for Health Research (NIHR) and Pfizer UK embark on exciting partnership to support health and care research leaders of the future in three key areas.
A first of its kind partnership is launching in April 2020, which will see Pfizer UK co-funding* NIHR Doctoral and Advanced fellowships with a focus on research in three key areas of unmet need - alopecia areata, chronic pain and atopic dermatitis.
The NIHR’s Fellowship Programme supports individuals on a trajectory to become future leaders in research. Through this novel partnership, the UK’s largest funder of health and care research and one of the world’s largest biopharmaceutical companies, can together drive innovation in key areas of health research and lead to breakthroughs that ultimately change patients’ lives.
At doctoral level, opportunities will be available to propose research in the area of chronic pain. Chronic pain affects up to a third of the population, it is defined as any pain that lasts for more than 3 months. The scale of long-term chronic pain in the UK has a significant impact on both the health and wealth of the nation. It has been referred to as a ‘silent epidemic’ by The British Pain Society,1 affecting patients’ quality of life, causing fatigue, loss of mobility,2 and comorbidities including mental health conditions such as anxiety and depression.3
For advanced post-doctoral fellowships, opportunities will be available to propose research in either atopic dermatitis or alopecia areata.
Atopic dermatitis (AD), also known as eczema, is the most common chronic inflammatory skin disease,4 affecting 1 in 5 children and 1 in 12 adults in the UK.5 Beyond the intense itch and discomfort caused by AD, sleep loss, diminished self-esteem and poor performance at school and work are associated with the condition.5,6
Alopecia areata is a common cause of non-scarring hair loss.7 The exact causes are still unclear but the evidence suggests that alopecia areata results from an abnormality in the immune system that damages hair follicles and disrupts normal hair formation. It is an area of high unmet medical need and can be psychologically devastating.8
The application process for all NIHR doctoral and advanced fellowships, including those co-funded by Pfizer, will open on 1 April 2020. For more information regarding the fellowships visit www.nihr.ac.uk/fellowships or email [email protected].
*Pfizer has provided 50% of the funding for this project as an Independent Research Fund Grant. Pfizer has provided a grant only and has no other involvement in the fellowship.
- The British Pain Society. (2016). The silent epidemic – chronic pain in the UK Accessed Nov 2021.
- Arthritis and Musculoskeletal Alliance 2019. Chronic Pain – This Is How It Feels Accessed Nov 2021.
- Lépine, J. & Briley, M. The epidemiology of pain in depression. Human Psychopharmacology, vol. 19, no. S1, pp. S3-S7, 2004 Accessed Nov 2021.
- Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nature Reviews Disease Primers. 2018;4(1):1.
- National Eczema Society. What is Eczema? Accessed Nov 2021.
- Fortson E, Feldman S, Strowd L. Stressors in Atopic Dermatitis. Management of Atopic Dermatitis. Adv Exp Med Biol. 2017;1027:71-77
- Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81-9.
- Wagner, A. Industry Perspective on Alopecia Areata. Journal of Investigative Dermatology Symposium Proceedings. 2015;17(2):67-69
PP-PFE-GBR-4227 / November 2021